What is Schedule III (Controlled Substances Act)?

Schedule III of the Controlled Substances Act (CSA) is a federal drug classification category established by the Drug Enforcement Administration (DEA) for substances that have moderate to low potential for physical and psychological dependence, currently accepted medical use in treatment, and abuse potential less than Schedule I or II substances. Substances in Schedule III include anabolic steroids, ketamine, and certain barbiturates. The classification carries specific regulatory requirements: prescriptions can be written for up to 90 days with up to five refills within six months, and these substances can be stored in standard pharmacy conditions rather than requiring the high-security storage mandated for Schedule I and II drugs. Cannabis's reclassification to Schedule III represents a historic shift in federal drug policy. In May 2024, the DEA proposed moving cannabis from Schedule I (alongside heroin and LSD) to Schedule III, following recommendations from the Department of Health and Human Services. This reclassification acknowledges cannabis's accepted medical use and lower abuse potential compared to Schedule I substances. The implications for the cannabis industry are substantial. Schedule III status would allow cannabis businesses to claim standard federal tax deductions under Section 280E of the Internal Revenue Code, potentially saving companies millions in taxes annually. Currently, cannabis businesses cannot deduct ordinary business expenses, significantly impacting profitability. However, Schedule III classification maintains cannabis as a controlled substance under federal oversight. This means interstate commerce would still require DEA licensing, and state-legal cannabis programs would continue operating under federal-state tensions. Manufacturing, distribution, and research would fall under DEA regulation, similar to pharmaceutical controlled substances. The reclassification process involves a formal rulemaking period with public comments, making the timeline uncertain. Industry experts estimate implementation could take 12-24 months from the initial proposal. While Schedule III represents progress toward federal cannabis reform, it falls short of full legalization or descheduling that many advocates seek.